Abstract:Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as TGF-β and PDGFs), cytokines (including TNF-α, IL-1, IL-6, IL-10 and IL-4), and neurohumoral pathways trigger fibrogenic signaling cascades through binding to surface receptors, and activation of downstream signaling cascades. In addition, matricellular macromolecules are deposited in the remodeling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review manuscript discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction (HFrEF and HFpEF), genetic cardiomyopathies and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodeling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.

Relationship Between Platelet-Derived Growth Factors and Myocardial Fibrosis

Roles of platelet-derived growth factor and platelet-derived growth factor receptors in cardiovascular diseases

Myocardial fibrosis in right heart dysfunction

The Molecular Mechanism of Different Factors Caused Myocardial Fibrosis

Role and Possible Mechanism of PDGF Signaling Pathways During Process of Myocardial Fibrosis Induced by Aldosterone

Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy

Role of PI3K/Akt signaling pathway in cardiac fibrosis

Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials

Targeted myocardial fibrosis for improving the diagnosis and treatment of heart failure

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Research Progress in Pathogenesis of Myocardial Fibrosis in Radiation-Induced Heart Damage

Cardiac fibrosis.

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress

Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction

Critical role of PAFR/YAP1 positive feedback loop in cardiac fibrosis

Myocardial fibrosis from the perspective of the extracellular matrix: mechanisms to clinical impact

Proteomic Insights into Cardiac Fibrosis: from Pathophysiological Mechanisms to Therapeutic Opportunities

Transforming Growth Factor β–Induced Endothelial-to-Mesenchymal Transition: A Switch to Cardiac Fibrosis?

Research Progress of Traditional Chinese Medicine Based on TGF-β/Smad Signal Pathway in Preventing and Treating Myocardial Fibrosis in Heart Failure

Myofibroblasts and Fibrosis